Posaconazole
Noxafil, Noxafil PowderMix, and generics
Antifungal agent
| C | 3 | Yes | Yes | No |
| Key |
- Delayed release tabs: 100 mg
- Injection: 300 mg/16.7 mL (16.7 mL); contains EDTA and sulfobutyl ether-β-cyclodextrin (SBECD)
- Oral suspension: 40 mg/mL (105 mL); contains polysorbate 80 and sodium benzoate
- Delayed release oral suspension (Noxafil PowderMix): 300 mg powder packet to be mixed with 9 mL of mixing liquid to yield a 30 mg/mL oral suspension (8 powder packets); contains sorbitol
There's more to see -- the rest of this topic is available only to subscribers.
Citation
Hughes, Helen K., and Lauren K. Kahl, editors. "Posaconazole." Harriet Lane Handbook, 23rd ed., Elsevier, 2024. Harriet Lane, www.unboundmedicine.com/harrietlane/view/Harriet_Lane_Handbook/310234/all/Posaconazole.
Posaconazole. In: Hughes HKH, Kahl LKL, eds. Harriet Lane Handbook. Elsevier; 2024. https://www.unboundmedicine.com/harrietlane/view/Harriet_Lane_Handbook/310234/all/Posaconazole. Accessed July 20, 2026.
Posaconazole. (2024). In Hughes, H. K., & Kahl, L. K. (Eds.), Harriet Lane Handbook (23rd ed.). Elsevier. https://www.unboundmedicine.com/harrietlane/view/Harriet_Lane_Handbook/310234/all/Posaconazole
Posaconazole [Internet]. In: Hughes HKH, Kahl LKL, eds. Harriet Lane Handbook. Elsevier; 2024. [cited 2026 July 20]. Available from: https://www.unboundmedicine.com/harrietlane/view/Harriet_Lane_Handbook/310234/all/Posaconazole.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Posaconazole
ID - 310234
ED - Hughes,Helen K,
ED - Kahl,Lauren K,
BT - Harriet Lane Handbook
UR - https://www.unboundmedicine.com/harrietlane/view/Harriet_Lane_Handbook/310234/all/Posaconazole
PB - Elsevier
ET - 23
DB - Harriet Lane
DP - Unbound Medicine
ER -

Harriet Lane Handbook

